7 completed, 2 active not recruiting, 2 not yet recruiting, 2 recruiting. 17 Phase 2, 6 Phase 3, 4 Phase 1.
Follow Thyroid Eye Disease: new trials by email Literature Review of Thyroid Eye Disease trials Research Report on Thyroid Eye Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO) Atorvastatin - Graves Disease, Graves Disease (Basedow's Disease) | Phase 2 | Not yet recruiting | Region Skane | 554 | 2026-11-01 | 2026-10-20 |
| An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease AMG 732 - Thyroid Eye Disease | Phase 2 | Recruiting | Amgen | 30 | 2026-05-07 | 2026-07-23 |
| An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED) NTB003, NTB003 and Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Not yet recruiting | Nanjing Chia-tai Tianqing Pharmaceutical | 74 | 2026-03-01 | 2026-03-10 |
| A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease IBI311 (20 mg), IBI311 (3-20 mg), IBI311 (10 mg) - Thyroid Eye Disease | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 38 | 2024-09-04 | 2025-10-03 |
| A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease AMG 732, Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Active not recruiting | Amgen | 94 | 2024-05-30 | 2026-08-10 |
| A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease LASN01, Placebo - Thyroid Eye Disease, Graves Ophthalmopathy | Phase 2 | Completed | Lassen Therapeutics Inc. | 41 | 2024-03-05 | 2026-03-09 |
| A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease TOUR006 - 20 MG, Placebo, TOUR006 - 50 MG - Thyroid Eye Disease | Phase 2 | Active not recruiting | Tourmaline Bio, Inc., a Novartis Company | 79 | 2024-02-19 | 2026-04-23 |
| Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) linsitinib - Thyroid Eye Disease, Graves Orbitopathy | Phase 2 / Phase 3 | Recruiting | Sling Therapeutics, Inc. | 75 | 2023-10-11 | 2025-02-25 |
| Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED) lonigutamab, Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Completed | ACELYRIN Inc. | 31 | 2023-02-14 | 2025-07-01 |
| A Study of IBI311 in Subjects With Active Thyroid Eye Disease IBI311, placebo - Thyroid Eye Disease | Phase 2 / Phase 3 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 115 | 2023-02-14 | 2024-02-08 |
| The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Methylprednisolone + ASTED, Methylprednisolone +Placebo - Thyroid Eye Disease | Phase 2 / Phase 3 | Withdrawn | Iran University of Medical Sciences | 2022-09-01 | 2022-01-10 | |
| A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Linsitinib, Placebo - Thyroid Eye Disease, Graves Orbitopathy | Phase 2 / Phase 3 | Completed | Sling Therapeutics, Inc. | 90 | 2022-07-01 | 2026-09-23 |
| A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease LASN01, Placebo - Pulmonary Fibrosis, Thyroid Eye Disease | Phase 1 / Phase 2 | Completed | Lassen Therapeutics 1 PTY LTD | 75 | 2022-06-06 | 2024-12-30 |
| Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease peri-levator betamethasone injection, peri-levator triamcinolone injection, peri-levator and retrobulbar betamethasone injection - Thyroid Eye Disease | Phase 2 / Phase 3 | Completed | Assiut University | 92 | 2021-12-01 | 2023-11-14 |
| Anti-VEGF Therapy for Acute Thyroid Eye Disease Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) alone - Thyroid Eye Disease | Phase 2 | Terminated | Massachusetts Eye and Ear Infirmary | 8 | 2020-11-02 | 2026-10-20 |
| The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) ASTED, Selenium, Placebo - Thyroid Eye Disease | Phase 2 / Phase 3 | Withdrawn | Iran University of Medical Sciences | 2019-07-15 | 2023-09-28 | |
| Celecoxib for Thyroid Eye Disease Celecoxib, artificial tears - Thyroid Eye Disease | Phase 2 | Terminated | Johns Hopkins University | 7 | 2017-03-05 | 2020-07-31 |
Graves Ophthalmopathy (17) · Exophthalmos (4) · Eye Diseases (4) · Endocrine System Diseases (3) · Orbital Diseases (3) · Thyroid Diseases (3) · Graves Disease (2) · Hashimoto Disease (2) · Hyperthyroidism (1) · Motor Activity (1) · Pulmonary Fibrosis (1)
Autoimmune Diseases (17) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (17) · Eye Diseases, Hereditary (17) · Genetic Diseases, Inborn (17) · Goiter (17) · Immune System Diseases (17) · Hyperthyroidism (16) · Graves Disease (15) · Endocrine System Diseases (14) · Orbital Diseases (14) · Thyroid Diseases (14) · Exophthalmos (13) · Eye Diseases (13) · Thyroiditis (2) · Thyroiditis, Autoimmune (2)
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (2) · Atorvastatin (1) · Celecoxib (1) · Lubricant Eye Drops (1) · Methylprednisolone (1) · Selenium (1) · Single Person (1)
Amgen (2) · Innovent Biologics (Suzhou) Co. Ltd. (2) · Iran University of Medical Sciences (2) · Sling Therapeutics, Inc. (2) · ACELYRIN Inc. (1) · Assiut University (1) · Johns Hopkins University (1) · Lassen Therapeutics 1 PTY LTD (1) · Lassen Therapeutics Inc. (1) · Massachusetts Eye and Ear Infirmary (1) · Nanjing Chia-tai Tianqing Pharmaceutical (1) · Region Skane (1) · Tourmaline Bio, Inc., a Novartis Company (1)
United States (9) · Spain (5) · Australia (3) · Italy (3) · Canada (2) · China (2) · France (2) · Iran (2) · Poland (2) · Taiwan (2) · United Kingdom (2) · Brazil (1) · Egypt (1) · Germany (1) · Greece (1)
Mohsen B Kashkouli, MD (2) · Ahmed Abdelal, MD (1) · Mohamed Shehata, MD (1) · Nahoung Grace Lee, MD (1) · Salma Kedwany, MD (1) · Tereza Planck (1) · Timothy J McCulley, MD (1)
2023 (1)